| 1269250 |
Regulation of Complement cascade |
4.35E–05 |
3 |
CFH, C3, C7 |
| SMP00101 |
Suprofen Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00104 |
Indomethacin Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00109 |
Mefanamic acid Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00113 |
Oxaprozin Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00114 |
Nabumetone Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00120 |
Naproxen Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00289 |
Diflunisal Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00077 |
Piroxicam Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00085 |
Ketoprofen Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00086 |
Ibuprofen Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00094 |
Sulindac Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00093 |
Diclofenac Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| SMP00098 |
Ketorolac Pathway |
1.34E–04 |
2 |
PLA2G2A, PTGIS |
| 1457777 |
Antimicrobial peptides |
1.45E–04 |
4 |
S100A8, PLA2G2A, DEFB1, GNLY |
| SMP00102 |
Bromfenac Pathway |
1.78E–04 |
2 |
PLA2G2A, PTGIS |
| M22072 |
Alternative Complement Pathway |
2.28E–04 |
2 |
C3, C7 |
| 1269241 |
Complement cascade |
3.52E–04 |
3 |
CFH, C3, C7 |
| M39649 |
Complement and Coagulation Cascades |
4.57E–04 |
3 |
CFH, C3, C7 |
| M4732 |
Lectin Induced Complement Pathway |
4.91E–04 |
2 |
C3, C7 |
| M7146 |
Classical Complement Pathway |
6.59E–04 |
2 |
C3, C7 |
| M16894 |
Complement and coagulation cascades |
7.24E–04 |
3 |
CFH, C3, C7 |
| 1427857 |
Regulation of TLR by endogenous ligand |
7.52E–04 |
2 |
S100A8, LY96 |
| M39770 |
Epithelial to mesenchymal transition in colorectal cancer |
7.92E–04 |
4 |
FZD7, TMPRSS4, CLDN11, CLDN3 |
| M3952 |
Cells and Molecules involved in local acute inflammatory response |
8.51E–04 |
2 |
C3, C7 |
| M39733 |
Cells and Molecules involved in local acute inflammatory response |
8.51E–04 |
2 |
C3, C7 |
| SMP00083 |
Acetylsalicylic Acid Pathway |
8.51E–04 |
2 |
PLA2G2A, PTGIS |
| PW:0000485 |
eicosanoids metabolic |
9.56E–04 |
2 |
PLA2G2A, PTGIS |
| MAP00590 |
MAP00590 Prostaglandin and leukotriene metabolism |
1.07E–03 |
2 |
PLA2G2A, PTGIS |
| 83073 |
Complement and coagulation cascades |
1.07E–03 |
3 |
CFH, C3, C7 |
| M917 |
Complement Pathway |
1.18E–03 |
2 |
C3, C7 |
| SMP00106 |
Meloxicam Pathway |
1.18E–03 |
2 |
PLA2G2A, PTGIS |
| SMP00116 |
Valdecoxib Pathway |
1.18E–03 |
2 |
PLA2G2A, PTGIS |
| SMP00084 |
Etodolac Pathway |
1.18E–03 |
2 |
PLA2G2A, PTGIS |
| SMP00087 |
Rofecoxib Pathway |
1.18E–03 |
2 |
PLA2G2A, PTGIS |
| SMP00096 |
Celecoxib Pathway |
1.18E–03 |
2 |
PLA2G2A, PTGIS |
| M39502 |
Complement Activation |
1.43E–03 |
2 |
C3, C7 |
| M39398 |
Allograft Rejection |
1.52E–03 |
3 |
C3, GNLY, C7 |
| M264 |
Endogenous TLR signaling |
1.71E–03 |
2 |
S100A8, LY96 |
| 1474301 |
IL-17 signaling pathway |
1.72E–03 |
3 |
S100A8, CCL2, CXCL2 |
| M39382 |
Eicosanoid Synthesis |
2.00E–03 |
2 |
PLA2G2A, PTGIS |
| M39581 |
Human Complement System |
2.06E–03 |
3 |
CFH, C3, C7 |
| M40056 |
16p11.2 distal deletion syndrome |
2.16E–03 |
2 |
C3, PLN |
| PW:0000138 |
Vitamin B6 metabolic |
2.58E–03 |
1 |
AOX1 |
| 1270236 |
Tight junction interactions |
2.84E–03 |
2 |
CLDN11, CLDN3 |
| M39341 |
Spinal Cord Injury |
3.47E–03 |
3 |
PLA2G2A, CCL2, CXCL2 |
| M11355 |
Tight junction |
4.64E–03 |
3 |
CLDN11, CLDN3, MYH11 |
